Get the Stockscreener App
1.1576
8.66%
-0.1124
Lyell Immunopharma Inc stock is traded at $1.1576, with a volume of 793.32K.
It is down -8.66% in the last 24 hours and down -4.92% over the past month.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
See More
Previous Close:
$1.27
Open:
$1.32
24h Volume:
793.32K
Relative Volume:
0.79
Market Cap:
$325.87M
Revenue:
$54,000
Net Income/Loss:
$-210.26M
P/E Ratio:
-1.3781
EPS:
-0.84
Net Cash Flow:
$-159.01M
1W Performance:
+22.35%
1M Performance:
-4.92%
6M Performance:
-50.85%
1Y Performance:
-45.79%
1-Day Range:
$1.14
$1.34
1-Week Range:
$0.85
$1.34
52-Week Range:
$0.85
$3.2556
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Name
Lyell Immunopharma Inc
Sector
Industry
Phone
650 695-0677
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-11-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-17-22 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | BofA Securities | Buy |
| Jul-12-21 | Initiated | Goldman | Buy |
| Jul-12-21 | Initiated | JP Morgan | Overweight |
| Jul-12-21 | Initiated | Morgan Stanley | Overweight |
View All
Lyell Immunopharma Inc Stock (LYEL) Latest News
Lyell Announces Presentation of Initial Clinical Data from - GlobeNewswire
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting - StockTitan
Vanguard Group Inc's Strategic Reduction in Lyell Immunopharma I - GuruFocus.com
Lyell shares down as BofA double downgrades to Sell - MSN
Lyell Immunopharma (NASDAQ:LYEL) Downgraded to “Underperform” Rating by Bank of America - Defense World
Lyell Immunopharma Completes Acquisition of ImmPACT Bio - The Manila Times
Lyell Immunopharma acquires ImmPACT Bio to boost CAR T-cell therapy - Investing.com India
B of A Securities Downgrades Lyell Immunopharma (LYEL) - MSN
Lyell Immunopharma’s (LYEL) “Neutral” Rating Reiterated at HC Wainwright - Defense World
Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy - Benzinga
Lyell shares down as BofA double downgrades to Sell By Investing.com - Investing.com South Africa
Lyell cut to underperform by BofA, pipeline reorganization cited - MSN
Lyell Immunopharma (NASDAQ:LYEL) Lowered to Underperform Rating by Bank of America - MarketBeat
HC Wainwright Reiterates Neutral Rating for Lyell Immunopharma (NASDAQ:LYEL) - MarketBeat
Lyell Immunopharma’s Acquistion of ImmPACT Bio USA - Global Legal Chronicle
Lyell Will Seek To Improve On Existing CAR-Ts Via Merger With ImmPACT - Citeline
Lyell Immunopharma stock hits 52-week low at $1.05 By Investing.com - Investing.com Australia
Lyell goes all in on CAR-T therapies, buys ImmPACT Bio and trims pipeline - Pharmaceutical Technology
Lyell Immunopharma stock hits 52-week low at $1.05 - Investing.com
Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth (NASDAQ:LYEL) - Seeking Alpha
Lyell, in search of a turnaround, to buy cell therapy startup ImmPact - BioPharma Dive
Lyell boosts pipeline with ImmPACT acquisition - Investing.com India
Lyell Immunopharma to Buy ImmPact; Refocuses Pipeline on T-Cell Cancer Treatments - MarketWatch
Lyell Immunopharma to acquire ImmPACT Bio (NASDAQ:LYEL) - Seeking Alpha
Lyell boosts pipeline with ImmPACT acquisition By Investing.com - Investing.com South Africa
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes - GlobeNewswire
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies - StockTitan
Lyell Immunopharma Inc (LYEL) deserves deeper analysis - US Post News
The Manufacturers Life Insurance Company Grows Stock Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Large Decline in Short Interest - MarketBeat
Lyell Immunopharma Inc (LYEL Stock: A Sea of Opportunity - The InvestChronicle
Lyell Immunopharma stock hits 52-week low at $1.09 - Investing.com
Lyell Immunopharma stock hits 52-week low at $1.09 By Investing.com - Investing.com UK
ProShare Advisors LLC Cuts Stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting - The Manila Times
Lyell Immunopharma Announces the Acceptance Abstracts for - GlobeNewswire
An analyst sees good growth prospects for Lyell Immunopharma Inc (LYEL) - SETE News
XTX Topco Ltd Has $102,000 Stock Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Lyell Immunopharma Inc (LYEL) Stock: A Year of Declines and Increases - The InvestChronicle
LYEL underperforms with a -0.66 decrease in share price - US Post News
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Shares Sold by Rhumbline Advisers - Defense World
The Significance of Moving Averages in Lyell Immunopharma Inc Inc. (LYEL) Price Performance - The InvestChronicle
Lyell Immunopharma Inc Stock (LYEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):